Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. It blocks viral entry into host cells while preserving normal immunologic function. The Company is also investigating an intramuscular method of administration of Trogarzo. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy.

TSX:TH - Post by User

Theratechnologies Inc > Anyone think it was odd

<< Previous

Bullboard Posts

Next >>

Comment by MHemorrhageon Feb 15, 2021 7:30am

88 Views

Post# 32567313

RE:RE:RE:RE:RE:RE:RE:Anyone think it was odd

Thank you, editing this in!

jfm1330 wrote:

My version of this part.

Their cancer drugs TH1902 and TH1904 are peptide-drug conjugates (PDCs). The proprietary peptide (TH19P01) is a ligand to sortilin, a receptor expressed in many types of cancer and also a drug carrier since different drugs can be linked covalently to the it by a selectively cleavable linker. In the case of TH1902 the drug linked to the peptide is doxorubicin, and in the case of TH1904, it is docetaxel, both are generic, highly toxic, well known anti-cancer drugs. The innovative approach for the cancer program is that the PDCs allows to deliver free cytotoxic agents inside the cancer cells while protecting healthy cells. So the peptide part of the PDC allows the linking of the cytotoxic drugs on it while retaining the abilty of specific binding to the sortilin receptor expressed on the outside membrane of cancer cells. Once the PDC is bound to the sortilin receptor, both are internalized into the cancer cell through a process called endocytosis. Once inside the cancer cell, the higher acidity, in comparison with the bloodstream, allows the cleavage of the linker and the release of the free anticancer agent. The key to this oncology platform is the overexpression of the sortilin receptor in many types of cancer. The sortilin receptor is the target to allow selective intake of the drug into the cancer cell. The other key part is the 17 amino acids peptide that has high affinity to the sortilin receptor that will lead to the specific binding of the two parts. The other critical feature of the peptide is the possibility to link to it two drug molecules through the use of a linker stable in the bloodstream, but unstable inside the cancer cells due to higher acidity. So this platform through the use of a proprietary peptide allows the selective intracellular delivery of cancer drugs. The advantages of this technique is that it allows higher concentration of the drug in the cancer cells, and much lower concentration in other healthy cells, leading to higher anti-cancer efficacy and lower toxicity in animal models with human cancer xenograft overexpressing the sortilin receptor.